Abiopharma

🔍 Kang Andrew (Executive)

Company: Strategy Inc (MSTR)

Report Date: 2026-03-17

Detailed Transactions and Holdings:

• Holds 0 shares of Series A Perpetual Strife Preferred Stock (Direct)
  Date: 2026-03-17 | Code: H | shares_owned_after: 1,500.00
• Holds 0 shares of Series A Perpetual Stretch Preferred Stock (Direct)
  Date: 2026-03-17 | Code: H | shares_owned_after: 2,800.00
• Holds 0 shares of Series A Perpetual Stride Preferred Stock (Direct)
  Date: 2026-03-17 | Code: H | shares_owned_after: 2,250.00
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-03-17 | Code: H | shares_owned_after: 23,815.00
• Acquired 8,391 shares of Employee Stock Option (Right to buy) at $150.28 per share (Derivative)
  Date: 2026-03-17 | Code: A | Expires: 2036-03-17 | equity_swap_involved: false | shares_owned_after: 8,391.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 18,298 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-17 | Code: A | equity_swap_involved: false | shares_owned_after: 18,298.00 | transaction_form_type: 4 | Footnotes: F2, F3, F3
• Acquired 6,722 shares of Performance Stock Units (Derivative)
  Date: 2026-03-17 | Code: A | equity_swap_involved: false | shares_owned_after: 6,722.00 | transaction_form_type: 4 | Footnotes: F4, F4, F4

Footnotes:

• F1: 25 percent of the shares subject to this option vest on the first anniversary of the grant date, and an additional 25 percent of the shares originally subject to this option vest on each anniversary thereafter until the option is vested in full.
• F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of class A common stock of Strategy Inc ("Strategy").
• F3: 25 percent of these RSUs vest on the first anniversary of the grant date, and an additional 25 percent of the original number of RSUs vest on each anniversary thereafter until the RSUs are vested in full.
• F4: Each performance stock unit ("PSU") represents a contingent right to receive shares of Strategy class A common stock of between 0% and 200% of the target number of units, with the percentage determined based on Strategy's relative total shareholder return ("TSR") as compared to the TSR of members of the Nasdaq Composite Index over a three-year performance period (March 17, 2026 to March 16, 2029). Vesting is subject to certification by Strategy's Compensation Committee of the level of achievement of the performance goal and the participant's continued service through that date. The "target" number of PSUs is reported on this Form 4.